{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:11:47Z","timestamp":1786122707062,"version":"build-2736575974"},"reference-count":50,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Effective Altruism Long Term Future Fund"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Appl Biosaf."],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>In the United States, vaccine development is a complicated and multifaceted process governed by a myriad of regulatory authorities and structures. In addition to industry laboratory, clinical, and manufacturing best practices, biosecurity restrictions are also placed on vaccine development for \u201cselect agents,\u201d those agents that are considered to pose the greatest risk to public health. Regulations imposed on select agent vaccine development must necessarily be adaptable in consideration of the opinions and experiences of practitioners, but, to date, those involved in vaccine development for select agents have not been specifically represented in published studies assessing researcher viewpoints. The perspectives of this community thus represent a gap in our knowledge of the effects of regulations on biosecurity preparedness infrastructures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>In this study, we sought to capture personal experiences of scientists working on select agent vaccines, who face unique technical considerations that differ from other vaccine research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We interviewed U.S. Government researchers and independent contractors who are directly involved in creating vaccines to assess how the select agent regulations (SARs) affect vaccine development in the United States. These personal narratives were transcribed and compiled thematically, covering topics of financial and governmental incentives, administrative and regulatory challenges, subcontracting, personnel security measures, and safety and efficacy testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Across eight interviews, there was a consensus that the SARs, while burdensome, are fair provisions that mitigate the inherent risk of conducting select agent work. Their perspectives exhibited how the SARs are primarily relevant during the preclinical stage of vaccine development and generally restrict progression to later stages of development typical of nonselect agent vaccines. In addition, lacking government financial incentives, the need for subcontracting, and the limited availability of validated animal models, while not exclusive to SAR work, all serve as significant obstacles to researcher involvement and overall progress in select agent vaccine development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Collectively, these perspectives provide valuable insight into the strengths, weaknesses, and potential areas for improvement in the implementation of the SARs for select agent vaccine development. In addition, these accounts were complimentary of the SARs in ways not currently represented in the literature, which merits further evaluation by larger-scale studies of this subgroup as well as select agent researchers as a whole. These insights provide important context for future discussions of regulatory oversight and its impact on biosecurity preparedness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15356760251405831","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:08:02Z","timestamp":1769062082000},"page":"165-175","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Necessary, Important, and Room for Improvement: Researcher Perspectives on the Impacts of the Select Agent Regulations on Vaccine Development"],"prefix":"10.1177","volume":"31","author":[{"given":"Shreya K.","family":"Kalra","sequence":"first","affiliation":[{"name":"School of Health, Georgetown University, Washington, DC, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Parker","sequence":"additional","affiliation":[{"name":"Office of the Dean, College of Arts &amp; Sciences, Georgetown University, Washington, DC, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"e_1_3_4_2_2","volume-title":"How Vaccines Are Developed and Approved for Use","author":"CDC","year":"2024","unstructured":"CDC. How Vaccines Are Developed and Approved for Use. CDC; 2024."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.7774\/cevr.2015.4.1.46"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9550-9_12"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piae036"},{"key":"e_1_3_4_6_2","unstructured":"Anonymous. Annex 2 Guidelines on the Nonclinical Evaluation of Vaccine Adjuvants and Adjuvanted Vaccines. n.d."},{"key":"e_1_3_4_7_2","volume-title":"Biosafety in Microbiological and Biomedical Laboratories","author":"Centers for Disease Control and Prevention","unstructured":"Centers for Disease Control and Prevention. Biosafety in Microbiological and Biomedical Laboratories, 6th Edition. n.d.","edition":"6"},{"key":"e_1_3_4_8_2","unstructured":"Animal and Plant Health Inspection Service. Possession Use and Transfer of Select Agents and Toxins. 2024. Available from: https:\/\/www.ecfr.gov\/current\/title-9\/chapter-I\/subchapter-E\/part-121"},{"key":"e_1_3_4_9_2","unstructured":"Animal and Plant Health Inspection Service. Possession Use and Transfer of Select Agents and Toxins. 2024."},{"key":"e_1_3_4_10_2","unstructured":"Department of Health and Human Services. Select Agents and Toxins. 2024."},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801885-9.00010-X"},{"key":"e_1_3_4_12_2","unstructured":"Anonymous. The FDA\u2019s Drug Review Process: Ensuring Drugs Are Safe and Effective. FDA; n.d. Available from: https:\/\/www.fda.gov\/drugs\/information-consumers-and-patients-drugs\/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective [Last accessed: November22 2024]."},{"key":"e_1_3_4_13_2","unstructured":"Anonymous. Animal Rule Information. n.d."},{"key":"e_1_3_4_14_2","author":"House Energy and Commerce Subcommittee on Health","unstructured":"House Energy and Commerce Subcommittee on Health. Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, n.d.","journal-title":"Pandemic and All-Hazards Preparedness Reauthorization Act of 2013"},{"key":"e_1_3_4_15_2","unstructured":"Anonymous. Overview of the Animal Model Qualification Program. FDA; n.d. Available from: https:\/\/www.fda.gov\/drugs\/animal-model-qualification-program-amqp\/overview-animal-model-qualification-program [Last accessed: September9 2025]."},{"key":"e_1_3_4_16_2","volume-title":"Protecting the Frontline in Biodefense Research: The Special Immunizations Program","author":"Council NR","year":"2011","unstructured":"Council NR. Protecting the Frontline in Biodefense Research: The Special Immunizations Program. The National Academies Press: Washington, DC; 2011; doi: 10.17226\/13112"},{"key":"e_1_3_4_17_2","volume-title":"Protecting the Frontline in Biodefense Research: Regulations and Other Guidance Pertaining to the Development and Use of Vaccines in the Special Immunizations Program","author":"Anonymous","year":"2011","unstructured":"Anonymous. Protecting the Frontline in Biodefense Research: Regulations and Other Guidance Pertaining to the Development and Use of Vaccines in the Special Immunizations Program. National Academies Press: Washington, D.C.; 2011; doi: 10.17226\/13112"},{"key":"e_1_3_4_18_2","volume-title":"Protecting the Frontline in Biodefense Research: New Vaccine Development and the Future Needs of the Special Immunizations Program","author":"Anonymous","year":"2011","unstructured":"Anonymous. Protecting the Frontline in Biodefense Research: New Vaccine Development and the Future Needs of the Special Immunizations Program. National Academies Press: Washington, DC; 2011; doi: 10.17226\/13112"},{"key":"e_1_3_4_19_2","unstructured":"Burkhalter K Vander Linden C. Department of Defense Transitions Legacy Special Immunization Program to Commercial Partners. 2024. Available from: https:\/\/www.army.mil\/article\/273807\/department_of_defense_transitions_legacy_special_immunization_program_to_commercial_partners [Last accessed: November22 2024]."},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.06.003"},{"key":"e_1_3_4_21_2","article-title":"Before monkeypox outbreak, U.S. officials knew for years they didn\u2019t have enough of key shot","author":"Banco E","year":"2022","unstructured":"Banco E, , Collis H. Before monkeypox outbreak, U.S. officials knew for years they didn\u2019t have enough of key shot. Politico, 2022.","journal-title":"Politico"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.48091\/gsr.v2i2.46"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/FPUBH.2021.612541"},{"key":"e_1_3_4_24_2","volume-title":"International Coordinating Group (ICG) on Vaccine Provision","author":"Word Health Organization","unstructured":"Word Health Organization. International Coordinating Group (ICG) on Vaccine Provision. WHO; n.d."},{"key":"e_1_3_4_25_2","unstructured":"Kalra S. Interview with Researcher A. 2023."},{"key":"e_1_3_4_26_2","unstructured":"Kalra S. Interview with Researcher D. 2023."},{"key":"e_1_3_4_27_2","unstructured":"Kalra S. Interview with Researcher B. 2023."},{"key":"e_1_3_4_28_2","unstructured":"Kalra S. Interview with Researcher E. 2023."},{"key":"e_1_3_4_29_2","unstructured":"Kalra S. Interview with Researcher C. 2023."},{"key":"e_1_3_4_30_2","unstructured":"Miller J. Postal Anthrax Aftermath: Has Biodefense Spending Made Us Safer? 2008."},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/BSP.2013.0047"},{"key":"e_1_3_4_32_2","volume-title":"Biosecurity Challenges of the Global Expansion of High-Containment Biological Laboratories: Summary of a Workshop","author":"Hottes AK","year":"2012","unstructured":"Hottes AK, , Ben R, , FEllen S. Biosecurity Challenges of the Global Expansion of High-Containment Biological Laboratories: Summary of a Workshop. National Academies Press; 2012."},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12709"},{"key":"e_1_3_4_34_2","unstructured":"Anonymous. HHS Should Plan for Medical Countermeasure Development and Manufacturing Risks Report to Congressional Committees United States Government Accountability Office. 2023."},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/153567600400900206"},{"key":"e_1_3_4_36_2","volume-title":"2024 Annual Report of the Federal Select Agent Program","author":"Centers For Disease Control and Prevention, United States Department of Agriculture","year":"2025","unstructured":"Centers For Disease Control and Prevention, United States Department of Agriculture. 2024 Annual Report of the Federal Select Agent Program. CDC; 2025."},{"key":"e_1_3_4_37_2","unstructured":"Stemple K. BEI Resources Repository. n.d. Available from: https:\/\/www.niaid.nih.gov\/research\/bei-resources-repository [Last accessed: November22 2024]."},{"key":"e_1_3_4_38_2","unstructured":"CDC USDA. Guidance on the Inventory of Select Agents and Toxins: Appendix II. 2020."},{"key":"e_1_3_4_39_2","unstructured":"Anonymous. Compliance Req. Assoc. with Biological Materials. n.d."},{"key":"e_1_3_4_40_2","unstructured":"Kalra S. Interview with Researcher F. 2023."},{"key":"e_1_3_4_41_2","unstructured":"Kalra S. Interview with Researcher G. 2023."},{"key":"e_1_3_4_42_2","unstructured":"Kalra S. Interview with Researcher H. 2023."},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.3389\/FBIOE.2024.1474120"},{"key":"e_1_3_4_44_2","unstructured":"Anonymous. Key Facts About Vaccines to Prevent Mpox Disease. n.d. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/key-facts-about-vaccines-prevent-mpox-disease?mkt_tok=NDkwLUVIWi05OTkAAAGSOPZjEWWzRxKQ_o_PBqczsY8QJara9_jtlxXeTPVdnmukofUIqpDb-Xpap3q2oZFfkQ88AKxrvVemtl-ilYYf5DI71gWfdfgUc41YB3-Fq1ujxg [Last accessed: November22 2024]."},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/0300985810372506"},{"key":"e_1_3_4_46_2","volume-title":"Product Development Under the Animal Rule Guidance for Industry","author":"Food and Drug Administration","unstructured":"Food and Drug Administration. Product Development Under the Animal Rule Guidance for Industry. FDA; n.d."},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.0915002107"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01313-09"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10070795"},{"key":"e_1_3_4_50_2","volume-title":"Live Attenuated Hepatitis A Vaccine","author":"Anonymous","year":"2010","unstructured":"Anonymous. Live Attenuated Hepatitis A Vaccine. 2010."},{"key":"e_1_3_4_51_2","volume-title":"Optimizing the Nation\u2019s Investment in Academic Research: A New Regulatory Framework for the 21st Century","author":"National Academies of Sciences E and M","year":"2016","unstructured":"National Academies of Sciences E and M. Optimizing the Nation\u2019s Investment in Academic Research: A New Regulatory Framework for the 21st Century. National Academies of Sciences; 2016; doi: 10.17226\/21824"}],"container-title":["Applied Biosafety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15356760251405831","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15356760251405831","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15356760251405831","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T12:19:52Z","timestamp":1786105192000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15356760251405831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9,1]]}},"alternative-id":["10.1177\/15356760251405831"],"URL":"https:\/\/doi.org\/10.1177\/15356760251405831","relation":{},"ISSN":["1535-6760","2470-1246"],"issn-type":[{"value":"1535-6760","type":"print"},{"value":"2470-1246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]}}}